BioMed Central Infectious Diseases
HIV-associated lipodystrophy syndrome (HALS) is characterized by insulin resistance, abnormal lipid metabolism and redistribution of body fat. To date, there has been no quantitative summary of the effects of insulin sensitizing-agents for the treatment of this challenging problem. We searched MEDLINE, the Cochrane Library, clinical trial registries, conference proceedings and references for randomized trials evaluating rosiglitazone, pioglitazone or metformin in patients with evidence of HALS (last update December 2009). Two reviewers independently abstracted data and assessed quality using a standard form. We contacted authors for missing data and calculated weighted mean differences (WMD) and 95% confidence intervals (CI) for each outcome.
Dartmouth Digital Commons Citation
Sheth, Siddharth H. and Larson, Robin J., "The Efficacy and Safety of Insulin-Sensitizing Drugs in HIV-Associated Lipodystrophy Syndrome: A Meta-Analysis of Randomized Trials" (2010). Dartmouth Scholarship. 628.